EyePoint Pharmaceuticals

Press Releases

All Releases
View Summary EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
May 16, 2018
PDF 23.0 KB Add to Briefcase
View Summary EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results
May 8, 2018
PDF 38.7 KB Add to Briefcase
View Summary EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Apr 19, 2018
PDF 15.3 KB Add to Briefcase
View Summary EyePoint Pharmaceuticals' YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 18, 2018
PDF 21.2 KB Add to Briefcase
View Summary EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™
Apr 12, 2018
PDF 16.3 KB Add to Briefcase
View Summary pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc.
Mar 28, 2018
PDF 32.5 KB Add to Briefcase
View Summary pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis
Mar 19, 2018
PDF 17.3 KB Add to Briefcase
View Summary pSivida To Present at the 30th Annual ROTH Conference
Mar 5, 2018
PDF 16.6 KB Add to Briefcase
View Summary pSivida to Present at the 2018 BIO CEO & Investor Conference
Feb 9, 2018
PDF 12.9 KB Add to Briefcase
View Summary pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
Feb 7, 2018
PDF 34.1 KB Add to Briefcase
View Summary pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months
Feb 7, 2018
PDF 21.8 KB Add to Briefcase
View Summary pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Jan 24, 2018
PDF 14.2 KB Add to Briefcase
View Summary pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
Jan 8, 2018
PDF 17.7 KB Add to Briefcase
View Summary pSivida Granted Waiver by the FDA for New Drug Application Filing Fee
Jan 4, 2018
PDF 14.7 KB Add to Briefcase
View Summary pSivida to Present at the Annual Biotech Showcase Conference
Jan 2, 2018
PDF 12.2 KB Add to Briefcase
View Summary HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
Dec 14, 2017
PDF 20.2 KB Add to Briefcase
View Summary pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
Nov 7, 2017
PDF 27.7 KB Add to Briefcase
View Summary pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Oct 18, 2017
PDF 14.6 KB Add to Briefcase
View Summary pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
Oct 10, 2017
PDF 25.8 KB Add to Briefcase
View Summary pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs
Sep 26, 2017
PDF 16.6 KB Add to Briefcase
Showing 1-20 of 303 Page: 1 2 3 4 5 ... 16  Next 20
Add to Briefcase = add release to Briefcase

Search Investor Relations

EyePoint Pharmaceuticals